Read more

November 21, 2024
25 min listen
Save

The Data Behind Precision Medicine with Melody Harris

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

In this episode, host Shikha Jain, MD, speaks with Melody Harris about the evolution of precision medicine, what physicians and companies can do to help patients better understand precision oncology and more.

  • Welcome to another exciting episode of Oncology Overdrive 0:14
  • About Harris 0:20
  • The interview 1:11
  • Tell us about how you ended up in this niche role. 1:32
  • How did you make the decision to move from practicing law to transitioning your career into this space? 3:56
  • Jain and Harris on the “hype” around precision medicine. 7:11
  • What is the central thesis of the work at NeoGenomics? 10:36
  • What do you feel companies need to be doing to make expectations surrounding diagnoses more transparent for patients?11:49
  • Where do you think this is all going in the future? Where do you think we’ll be in another ten or twenty years?13:30
  • What do you see yourself doing next?19:04
  • How can companies address the disparities in health care access, especially in underserved areas?21:06
  • If someone could only listen to the last few minutes of this episode, what would you want listeners to take away? 23:32
  • How to contact Harris 24:30
  • Thanks for listening 25:14

Melody Harris serves as chief operations officer and president of informatics at NeoGenomics, a leading oncology testing services company.

We’d love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Harris can be reached at melody.harris@neogenomics.com.

Sources/Disclosures

Collapse

Disclosures: Jain and Harris report no relevant financial disclosures.